GE Healthcare expands cell therapy portfolio with license of STEMCELL Technologies’ T-Cell reagents
Chalfont St Giles, UK – 23 August 2016 – In a further step to build its portfolio for the rapidly-growing cell therapy industry, GE Healthcare today announced an agreement with STEMCELL Technologies Inc. of Vancouver, Canada to provide T-Cell reagents for commercial-scale cell therapy production. Under the agreement, GE Healthcare will commercialize cGMP-grade versions of... Read more